Abstract: Objective To evaluate the toxicity and efficacy of dendritic cells/cytokine-induced killer cells （DC/CIK） as the maintenance therapy for advanced non-small cell lung cancer （NSCLC）. Methods During January 2010 and January 2014， 120 advanced NSCLC patients in stable condition were enrolled after 4-6 cycles chemotherapy containing platinum. According to the treatment， patients were assigned into control group （n=65） and study group （n=55）. Only the study group received DC/CIK maintenance therapy. Both groups were followed up and the progression free survival （PFS） and overall survival （OS） were compared. Moreover， the adverse reaction was recorded. Results The median PFS and OS were 5.0 and 8.5 months in study group and 3.5 and 8.0 months in control group，respectively. The median PFS was higher in study group versus control group （P＜0.05）. No significant differences were observed on median OS between both groups. In addition，there were similar median PFS and OS between different chemotherapeutic efficacy of sub-group. The common adverse reaction included myelosuppression， fever， fatigue and joint pain. The differences of both groups were not statistically significant （P＞0.05）. Conclusion DC/CIK as the maintenance therapy can prolong the progression of advanced NSCLC patients in stable condition with tolerable and low adverse reaction.